

Targeting Amyloid β in the Management of Alzheimer's Disease

Ephrem Ashenafi¹, Kalkidan Asmamaw²

¹Department of Pharmacology and Clinical Pharmacy, School of Pharmacy, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia

²School of Medicine, College of Medical and Health Sciences, Dire Dawa University, Dire Dawa, Ethiopia

Abstract

Alzheimer's Disease (AD) is a ruthlessly progressive neurodegenerative disease that has been growing steadily. Amyloid beta (A β) peptide buildup in the brain is thought to play a crucial role in the instigation and/or advancement of Alzheimer's disease. Revisions to the amyloid cascade hypothesis now distinguish the delicate balance in which A β exists and the role played by the enzymes in the production and breakdown of A β in maintaining healthy A β levels. Several targets have been identified and a long list of compounds has been developed to treat and/or slow the progression of the disease. However, none has reached the clinical arena. In this review, we tried to discuss some potential targets for maintaining healthy levels of amyloid-beta.

